- Home
- SIGA vs MYGN Comparison
SIGA vs MYGN Comparison
Compare SIGA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- MYGN
- Stock Information
- Founded
- SIGA 1995
- MYGN 1991
- Country
- SIGA United States
- MYGN United States
- Employees
- SIGA N/A
- MYGN N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SIGA Health Care
- MYGN Health Care
- Exchange
- SIGA Nasdaq
- MYGN Nasdaq
- Market Cap
- SIGA 594.3M
- MYGN 625.5M
- IPO Year
- SIGA 1997
- MYGN 1995
- Fundamental
- Price
- SIGA $5.84
- MYGN $7.40
- Analyst Decision
- SIGA
- MYGN Hold
- Analyst Count
- SIGA 0
- MYGN 14
- Target Price
- SIGA N/A
- MYGN $13.23
- AVG Volume (30 Days)
- SIGA 466.5K
- MYGN 1.3M
- Earning Date
- SIGA 11-06-2025
- MYGN 11-03-2025
- Dividend Yield
- SIGA 10.40%
- MYGN N/A
- EPS Growth
- SIGA N/A
- MYGN N/A
- EPS
- SIGA 1.03
- MYGN N/A
- Revenue
- SIGA $172,249,641.00
- MYGN $825,300,000.00
- Revenue This Year
- SIGA N/A
- MYGN $0.06
- Revenue Next Year
- SIGA $115.06
- MYGN $5.68
- P/E Ratio
- SIGA $5.67
- MYGN N/A
- Revenue Growth
- SIGA N/A
- MYGN 0.21
- 52 Week Low
- SIGA $4.95
- MYGN $3.76
- 52 Week High
- SIGA $9.62
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- SIGA 23.55
- MYGN 55.39
- Support Level
- SIGA $5.80
- MYGN $6.43
- Resistance Level
- SIGA $6.05
- MYGN $6.89
- Average True Range (ATR)
- SIGA 0.33
- MYGN 0.48
- MACD
- SIGA -0.11
- MYGN 0.04
- Stochastic Oscillator
- SIGA 5.45
- MYGN 86.91
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.